Karyopharm Therapeutics Inc.

NasdaqGS:KPTI 주식 보고서

시가총액: US$96.9m

Karyopharm Therapeutics 관리

관리 기준 확인 3/4

Karyopharm Therapeutics CEO는 Richard Paulson, May2021 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $ 2.63M, 28.2% 로 구성됩니다. 28.2% 급여 및 71.8% 보너스(회사 주식 및 옵션 포함). 는 $ 255.17K 가치에 해당하는 회사 주식의 0.26% 직접 소유합니다. 255.17K. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 4.6 년입니다.

주요 정보

Richard Paulson

최고 경영자

US$2.6m

총 보상

CEO 급여 비율28.2%
CEO 임기3.5yrs
CEO 소유권0.3%
경영진 평균 재임 기간2.9yrs
이사회 평균 재임 기간4.6yrs

최근 관리 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Apr 27
Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

CEO 보상 분석

Richard Paulson 의 보수는 Karyopharm Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$3mUS$740k

-US$143m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$142m

Mar 31 2023n/an/a

-US$158m

Dec 31 2022US$7mUS$697k

-US$165m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$8mUS$468k

-US$124m

Sep 30 2021n/an/a

-US$206m

Jun 30 2021n/an/a

-US$208m

Mar 31 2021n/an/a

-US$201m

Dec 31 2020US$1mn/a

-US$196m

보상 대 시장: Richard 의 총 보상 ($USD 2.63M )은 US 시장( $USD 652.28K ).

보상과 수익: Richard 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Richard Paulson (57 yo)

3.5yrs

테뉴어

US$2,626,288

보상

Mr. Richard A. Paulson, M.B.A. has been a Director of Karyopharm Therapeutics Inc. since February 26, 2020 and has been its Chief Executive Officer and President since May 3, 2021. Mr. Paulson has been an...

리더십 팀

이름위치테뉴어보상소유권
Richard Paulson
President3.5yrsUS$2.63m0.26%
$ 255.2k
Sohanya Cheng
Executive VP2.9yrsUS$1.19m0.077%
$ 74.5k
Stuart Poulton
Executive VP & Chief Development Officer2.8yrsUS$1.11m0.032%
$ 31.0k
Reshma Rangwala
Executive VP2.6yrsUS$1.23m0.023%
$ 22.1k
Mansoor Mirza
Clinical Consultant14.8yrsUS$208.33k0%
$ 0
Sharon Shacham
Co-Founder & Chairman of Scientific Advisory Board16.8yrsUS$6.04m0.68%
$ 654.9k
Cameron Peters
Vice President of Finance5.8yrs데이터 없음데이터 없음
Elhan Webb
Senior Vice President of Investor Relations2.7yrs데이터 없음데이터 없음
Michael Mano
Senior VP3.9yrsUS$2.06m0.039%
$ 37.7k
James Accumanno
Chief Compliance Officer2.1yrs데이터 없음데이터 없음
Sarah Connors
Vice President of Corporate Communicationsno data데이터 없음데이터 없음
Lisa DiPaolo
Executive VP & Chief Human Resource Officer2.2yrs데이터 없음데이터 없음

2.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: KPTI 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Richard Paulson
President4.8yrsUS$2.63m0.26%
$ 255.2k
Mansoor Mirza
Clinical Consultant14.1yrsUS$208.33k0%
$ 0
Sharon Shacham
Co-Founder & Chairman of Scientific Advisory Boardno dataUS$6.04m0.68%
$ 654.9k
Chen Schor
Independent Director4yrsUS$128.33k0%
$ 0
Deepika Pakianathan
Independent Director11.6yrsUS$148.33k0%
$ 0
Garen Bohlin
Independent Director11.1yrsUS$138.33k0.036%
$ 34.9k
Barry Greene
Lead Independent Director11.8yrsUS$173.33k0.011%
$ 10.5k
Michael Savona
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Christy Oliger
Independent Director4.3yrsUS$138.33k0%
$ 0
Zhen Su
Independent Director1.3yrsUS$81.49k데이터 없음
Andrew Kung
Member of Scientific Advisory Board4.5yrs데이터 없음데이터 없음
Andrew Lassman
Member of Scientific Advisory Board4.5yrs데이터 없음데이터 없음

4.6yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: KPTI 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.